Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19

Tyrosine kinase inhibitors (TKIs) are used to target dysregulated signaling pathways in virtually all hematologic malignancies. Many of the targeted signaling pathways are also essential in nonmalignant immune cells. The current coronavirus severe acute respiratory syndrome coronavirus 2 pandemic ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Jacobs, Chaja F., Eldering, Eric, Kater, Arnon P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871903/
https://www.ncbi.nlm.nih.gov/pubmed/33560402
http://dx.doi.org/10.1182/bloodadvances.2020003768

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871903/
https://www.ncbi.nlm.nih.gov/pubmed/33560402
http://dx.doi.org/10.1182/bloodadvances.2020003768

Ejemplares similares